Perflurochemical treatment process and apparatus

• US 8,535,691 B2
• Filed: 02/16/2006
• Issued: 09/17/2013
• Est. Priority Date: 02/16/2006
• Status: Active Grant

• Current Assignee: Peach Technologies, LLC
• Original Assignee: Peach Technologies, LLC
• Inventors: Shaffer, Thomas H., Stern, Robert G., Wolfson, Marla R.
• Primary Examiner(s): Blanchard, David J
• Assistant Examiner(s): Kassa, Tigabu
• Application Number:
  US11/276,180
• Publication Number:
  US 20070190082A1
• Time in Patent Office: 2,770 Days
• Field of Search: None
• US Class Current: 424/400
• CPC Class Codes: A61G 10/023 Rooms for the treatment of patients at over- or under-pressure or at a variable pressure

Abstract

A subject is confined in a closed environment at an elevated pressure through which perfluorochemical fluid containing dissolved oxygen is circulated to treat disease or injury.

Claims

1. A process for treating a subject living organism, the process comprising:

(a) confining at least a portion of the organism in a closed environment;

(b) providing a circulating perfluorochemical fluid in the closed environment;

(c) dissolving a selected gaseous material in the perfluorochemical fluid to provide perfluorochemical fluid containing the dissolved selected material;

(d) providing a pressure differing from atmospheric pressure in the closed environment;

(e) immersing the at least a portion of the organism in the perfluorochemical fluid containing the selected gaseous material; and

(f) alternately pressurizing the closed environment to a first pressure and a second pressure, in a cycled manner, the pressure cycling employing cardiac gating, such that the variation of pressure is synchronized with cardiac rhythms.

2. The process according to claim 1 further comprising controlling the temperature of the closed environment.

3. The process according to claim 1 wherein the process is employed to promote the healing of an area of the body of a living organism affected by injury or disease, at least the affected area is confined in the closed environment, and the selected gaseous material is oxygen.

4. The process according to claim 1 further comprising varying the pressure according to a predetermined pressure variation program.

5. The process according to claim 2 further comprising varying the temperature of the closed environment according to a predetermined temperature variation program.

6. The process according to claim 1 further comprising providing a biologically active material in the perfluorochemical fluid.

7. The process according to claim 6 wherein the biologically active material is selected from the group consisting of tissue growth promoters, hormones, antibiotics, genetic delivery systems, and pharmaceutical delivery systems.

8. The process according to claim 1 wherein the perfluorochemical fluid is provided in a fluid form selected from the group consisting of liquid, nebulized, vaporized and aerosolized phases.

9. The process according to claim 1 wherein the perfluorochemical fluid comprises at least one fluorinated hydrocarbon having at least one-half of the corresponding hydrocarbon'"'"'s hydrogen atoms substituted by fluorine.

10. The process according to claim 9 wherein at least one fluorinated hydrocarbon is selected from the group consisting of C₄F₉CH═

CH₄C₉, i-C₃F₉CH═

CHC₆F₁₃, C₆F₁₃CH═

CHC₆F₁₃, C₁₀F₁₈, C₈F₁₇Br, (C₆F₁₃)2O, CF₃CFOCF₂CF₃, (CF₃)₂CFO(CF₂)₃CF₃, (CF₃)₂CFO(CF₂)₄OCF(CF₃)₂, (CF₃)₂CFO(CF₂)₆OCF(CF₃)₂, F-2-butyltetrahydrofuran, F-n-cyclohexylpyrrolidine, F-n-methyldecahydroquinoline, F-n-methyldecahydroisoquinoline, F-adamantane, F-methyladamantane, F-1,3-dimethyladamantane, F-dimethylbicyclo[3,3,1]nonane, F-trimethylbicyclo[3,3,1]nonane, F-tripropylamine, F-tributylamine, C-4 alkyl decalins C₁₄F₂₄/C₁₄F₂₆, C₁₀F₁₈, C₈F₁₇Br, C₆F₁₄-perfluorohexanes, and mixtures thereof.

11. The process according to claim 1 further comprising providing electrically charged particles in the perfluorochemical fluid.

12. The process according to claim 1 further comprising providing magnetically charged particles into the perfluorochemical fluid.

13. The process according to claim 1 further comprising dissolving other therapeutic gases in the perfluorochemical fluid to enhance the oxygenation of the perfluorochemical fluid.

14. The process according to claim 13 wherein other gases are selected from the group consisting of helium, nitric oxide, and other therapeutic gases.

15. The process according to claim 1 further comprising transmitting ultrasound through the liquid perfluorochemical fluid to the affected area, the ultrasound having a frequency selected from those employed in established practice for physical therapy of soft tissue or organ injuries.

16. The process according to claim 1 wherein the entire living organism is confined in the closed environment and further comprising providing respiration means to the living organism.

17. The process according to claim 1 wherein a portion of the living organism is confined in the closed environment.